Halozyme Therapeutics: Steady Growth In A Challenged Market

2025-03-14 16:13:09 ET

Summary

• Halozyme Therapeutics, Inc. has shown robust growth, with Q4 2024 earnings surpassing expectations and significant revenue increases driven by royalties from partnered products.
• The company's ENHANZE drug delivery platform enhances existing drugs, generating substantial royalties and milestone payouts, with key products like Darzalex SC and Phesgo key drivers of growth.
• Despite currently mixed analyst opinions, Halozyme Therapeutics, Inc.'s solid growth prospects and reasonable valuation merit an 'accumulate' rating, especially if the stock dips to the mid $50s.
• An updated analysis around HALO stock follows in the paragraphs below.

When I last looked at Halozyme Therapeutics, Inc. ( HALO ) in October of last year, I concluded the article by noting the company was a solid covered call candidate after the stock's recent decline. That recommendation has worked out well, as the equity has been one of the few in the space that has bucked the downward tilt of the sector and overall market here in 2025. The company also closed out 2024 on a high note with fourth quarter results that beat expectations when they were posted in February. So, what is ahead for Halozyme and its shareholders in 2025? An updated analysis follows in the paragraphs below....

Read the full article on Seeking Alpha

For further details see: